Group One Trading’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-1,000
| Closed | -$13.4K | – | 8322 |
|
|
2023
Q4 | $13.4K | Buy |
1,000
+300
| +43% | +$3.79K | ﹤0.01% | 6019 |
|
|
2023
Q3 | $8.63K | Buy |
+700
| New | +$8.48K | ﹤0.01% | 6429 |
|
|
2023
Q2 | – | Sell |
-2,600
| Closed | -$32K | – | 8525 |
|
|
2023
Q1 | $32K | Sell |
2,600
-16,500
| -86% | -$194K | ﹤0.01% | 5195 |
|
|
2022
Q4 | $219K | Buy |
+19,100
| New | +$157K | ﹤0.01% | 3793 |
|
|
2022
Q3 | – | Sell |
-5,600
| Closed | -$33K | – | 8725 |
|
|
2022
Q2 | $33K | Buy |
5,600
+4,400
| +367% | +$24.8K | ﹤0.01% | 5927 |
|
|
2022
Q1 | $8K | Buy |
+1,200
| New | +$6.74K | ﹤0.01% | 7278 |
|
|
2021
Q4 | – | Sell |
-98,500
| Closed | -$476K | – | 9250 |
|
|
2021
Q3 | $476K | Buy |
+98,500
| New | +$514K | ﹤0.01% | 4238 |
|
|
2021
Q1 | – | Sell |
-600
| Closed | -$4K | – | 8321 |
|
|
2020
Q4 | $4K | Sell |
600
-1,500
| -71% | -$7.4K | ﹤0.01% | 6139 |
|
|
2020
Q3 | $8K | Buy |
+2,100
| New | +$7.71K | ﹤0.01% | 5522 |
|
|
2020
Q1 | – | Sell |
-9,000
| Closed | -$28K | – | 6144 |
|
|
2019
Q4 | $28K | Buy |
+9,000
| New | +$36K | ﹤0.01% | 4256 |
|
|
2019
Q2 | – | Sell |
-1,525
| Closed | -$8K | – | 5754 |
|
|
2019
Q1 | $8K | Buy |
+1,525
| New | +$7.01K | ﹤0.01% | 4355 |
|
|
2018
Q4 | – | Sell |
-381
| Closed | -$2K | – | 5901 |
|
|
2018
Q3 | $2K | Sell |
381
-17,159
| -98% | -$72.3K | ﹤0.01% | 5053 |
|
|
2018
Q2 | $68K | Buy |
+17,540
| New | +$116K | ﹤0.01% | 3794 |
|
|
2017
Q3 | – | Sell |
-16,434
| Closed | -$160K | – | 5496 |
|
|
2017
Q2 | $160K | Sell |
16,434
-8,007
| -33% | -$164K | ﹤0.01% | 2811 |
|
|
2017
Q1 | $592K | Buy |
24,441
+13,599
| +125% | +$340K | 0.01% | 1730 |
|
|
2016
Q4 | $348K | Buy |
10,842
+6,152
| +131% | +$262K | ﹤0.01% | 2018 |
|
|
2016
Q3 | $234K | Sell |
4,690
-2,313
| -33% | -$96K | ﹤0.01% | 2357 |
|
|
2016
Q2 | $297K | Buy |
7,003
+6,762
| +2,806% | +$368K | ﹤0.01% | 2136 |
|
|
2016
Q1 | $16K | Sell |
241
-4,487
| -95% | -$234K | ﹤0.01% | 3865 |
|
|
2015
Q4 | $294K | Sell |
4,728
-12,354
| -72% | -$869K | ﹤0.01% | 2219 |
|
|
2015
Q3 | $1.14M | Buy |
17,082
+6,647
| +64% | +$543K | 0.02% | 1145 |
|
|
2015
Q2 | $1.01M | Buy |
10,435
+2,885
| +38% | +$275K | 0.01% | 1194 |
|
|
2015
Q1 | $706K | Buy |
7,550
+4,894
| +184% | +$417K | 0.01% | 1341 |
|
|
2014
Q4 | $236K | Sell |
2,656
-2,339
| -47% | -$170K | ﹤0.01% | 2167 |
|
|
2014
Q3 | $345K | Sell |
4,995
-26,145
| -84% | -$1.4M | 0.01% | 1906 |
|
|
2014
Q2 | $1.79M | Buy |
31,140
+20,298
| +187% | +$1.03M | 0.03% | 777 |
|
|
2014
Q1 | $430K | Buy |
10,842
+7,690
| +244% | +$329K | 0.01% | 1761 |
|
|
2013
Q4 | $132K | Buy |
3,152
+1,093
| +53% | +$31.7K | ﹤0.01% | 2801 |
|
|
2013
Q3 | $62K | Buy |
2,059
+318
| +18% | +$11.1K | ﹤0.01% | 3391 |
|
|
2013
Q2 | $92K | Buy |
+1,741
| New | +$76.3K | ﹤0.01% | 2905 |
|
Other funds holding MACK
RA
JC
Group One Trading's MACK Position: Q1 2024 in Review
Group One Trading sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2024, closing a stake of 236 shares — an estimated $3.32K sold.
Group One Trading first reported a position in MACK in Q3 2013 and held it in 26 quarters. The position peaked at $1.2M in Q1 2014. 70 funds tracked by Wall St. Rank hold MACK as of Q1 2024.
- Group One Trading reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2024 after selling out during the quarter.
- Group One Trading sold 236 Merrimack Pharmaceuticals, Inc. shares in Q1 2024, an estimated $3.32K.
- Group One Trading first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 26 quarters.
- Group One Trading's Merrimack Pharmaceuticals, Inc. position peaked at $1.2M in Q1 2014.
- 70 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2024.
Based on Group One Trading's 13F filing for Q1 2024, filed 10 May 2024.